Comparative Pharmacology
Head-to-head clinical analysis: BRIELLYN versus N E E 1 35 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRIELLYN versus N E E 1 35 28.
BRIELLYN vs N.E.E. 1/35 28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol (estrogen) and norethindrone (progestin) that inhibits gonadotropin secretion, primarily suppressing ovulation and altering cervical mucus and endometrial lining.
Combination oral contraceptive; ethinyl estradiol and norethindrone suppress gonadotropin (FSH and LH) release, preventing ovulation. Also cause cervical mucus thickening and endometrial changes.
BRIELLYN (ethinyl estradiol / norethindrone) 1 tablet (0.035 mg ethinyl estradiol / 0.5 mg norethindrone) orally once daily at the same time each day.
One tablet orally once daily for 28 days; each tablet contains norethindrone 1 mg and ethinyl estradiol 35 mcg.
None Documented
None Documented
12-19 hours; clinical context: steady state reached in 3-5 days, dosing adjustment recommended in renal impairment
Ethinyl estradiol: ~15-19 hours (linear pharmacokinetics); Norethindrone: ~7-9 hours (terminal half-life; steady-state achieved within 5-7 days)
Approximately 60% renal excretion of metabolites, 40% fecal/biliary elimination
Renal: ~50-60% (metabolites, primarily glucuronide conjugates); Fecal: ~30-40% (biliary excretion of metabolites); Unchanged drug: <5%
Category C
Category C
Oral Contraceptive
Oral Contraceptive